The UA pulmonary division hosts a free public lecture on interstitial lung diseases sponsored by the Pulmonary Fibrosis Foundation (PFF) on Friday, Dec. 8, noon-2:30 p.m., in the UA BIO5 Institute, Thomas W. Keating Building, Room 103.
Speaking will be Evans R. Fernández Pérez, MD, MS, associate professor of medicine, Division of Pulmonary, Critical Care and Sleep Medicine, and a member of the Interstitial Lung Disease Program and Autoimmune Lung Center at National Jewish Health in Denver.
This lecture also served as the initial lecture in the Winter Lung Series Conferences hosted by the UA Division of Pulmonary, Allergy, Critical Care and Sleep Medicine.
You also can see other speakers in the series and their topics at this link.
Community health care providers, patients and their families are invited to attend as they’ll have an opportunity to meet physicians and staff with the ILD Program at the UA College of Medicine – Tucson. The local program, through efforts of the UA Division of Pulmonary, Allergy, Critical Care and Sleep Medicine (PACCS), was accepted into the PFF Care Center Network in January 2015. The network offers access to a wealth of resources for patients and caregivers as well as collaborative opportunities among the 40 participating academic institutions to advance the care of patients with pulmonary fibrosis.
A light lunch will be served in the style of grand rounds. To RSVP, please contact PACCS administrative assistant Carol Debis-Harrell, email@example.com or (520) 626-3264.
Click here [PDF] (or on the image at left) to download, post and share the flyer for this event.
To add this event to your personal schedule (via iCal, Outlook, Google or Yahoo! calendar), click here.
You can also view this event live or, afterward, archived at the following link: https://streaming.biocom.arizona.edu/event/index.cfm?id=27999
Interstitial lung diseases encompass a range of illnesses (more than 130) that contribute to lung tissue thickening due to inflammation, scarring or extra fluid (edema), and may eventually lead to respiratory failure. Among these illnesses are idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, sarcoidosis, eosinophilic granuloma, pulmonary vasculitis, bronchiolitis obliterans, and lymphangioleiomyomatosis. Some are short-lived, others chronic and irreversible. Their treatment can be complicated also by autoimmune, rheumatoid and other conditions.
About the Speaker
Before joining the faculty at National Jewish Health in 2008, Dr. Fernandez was a fellow at Mayo Clinic (Rochester, MN) where he completed fellowships in pulmonary medicine (2006-08) and critical care medicine (2004-06). While at Mayo, he served as chief fellow for critical care medicine and won Mayo’s Critical Care Meritorious Research Award for Outstanding Research Achievement as well as a Chest Foundation Young Investigator Award in 2007 from the American College of Chest Physicians. He did his residency in internal medicine at Beth Israel University Hospital and Manhattan Campus for the Albert Einstein College of Medicine in New York (2001-04).
Dr. Fernández’ specialties include autoimmune diseases, rheumatoid conditions, critical care and pulmonary medicine. The most recent articles he has co-authored on ILD include:
- “High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival” — Respiratory Medicine, May 2017 (PMID 28427540).
- “Clinical Predictors of Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease” — Annals of the American Thoracic Society, July 2016 (PMID: 27064856).
- “Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease” — European Respiratory Journal, February 2016 (PMID: 26585429).
About the Lecture
Continuing medical education (CME) credits—1.0 AMA PRA Category 1 Credit(s)™—are offered for this lecture through a providership agreement between PFF and The France Foundation (TFF) in accordance with requirements of the Accreditation Council for Continuing Medical Education.
This event is part of an annual PFF education event offered through the UA pulmonary division (PACCS) for community providers and patients, said Sachin Chaudhary, MD (right), a UA assistant professor of medicine and pulmonary and critical care specialist who also is UA director of the ILD Program at Banner – University Medical Center Tucson and South, and director of Respiratory Services & Bronchoscopy at Banner – UMC South.
Dr. Chaudhary helped arranged the lecture and choose the speaker through TFF, which collaborates with the PFF to expand educational offerings on interstitial lung diseases (ILD) through TFF’s PILOT™ (Pulmonary Fibrosis Identification: Lessons for Optimizing Treatment) initiative.
He added that the UA’s affiliation with the Pulmonary Fibrosis Foundation as a member of its PFF Care Center Network since 2015 has greatly benefited the ILD Program and patients.
“It has helped us grow as a center and we have now over 650 patients with various interstitial lung diseases. We have a local registry for these patients as well as through PFF. It has put us on the national map as one of the centers for treating rare interstitial lung diseases. It’s a great resource for patients as we have support groups literature that we provide to all our patients,” Dr. Chaudhary said.
About the Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation (PFF) mobilizes people and resources to provide access to high quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives. The PFF collaborates with physicians, organizations, people with pulmonary fibrosis and caregivers worldwide. Founded in 2013, the PFF Care Center Network includes 40 sites in more than 20 states that use a multidisciplinary approach to deliver comprehensive patient care, forming specialized care teams comprised of experts in interstitial lung disease in pulmonary medicine, rheumatology, radiology and pathology. This multidisciplinary approach is critical to managing a complex disease like PF and ensuring people with PF receive an accurate diagnosis, obtain quality clinical care and acquire important support services. Learn more at pulmonaryfibrosis.org
Original post 11 a.m., Nov. 27, 2017 | Updated 8:30 a.m., Nov. 30, 2017